Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Original) A compound of Formula I:



(I)

wherein:

D^1 is a C_1-C_3 alkane-diyl;

D^2 is CH or nitrogen;

D^4 is oxygen or sulfur;

R^1 is phenyl,

which phenyl is optionally substituted with one to three substitutents independently selected from the group consisting of halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy;

R^2 is selected from the group consisting of hydroxy, C_1-C_4 alkyl, optionally substituted phenyl, naphthyl, C_3-C_{10} cycloalkyl, pyridyl, optionally substituted pyrrolidinyl, optionally substituted piperidinyl,

which C_1-C_4 alkyl is optionally substituted with hydroxy, C_1-C_2 alkoxy, optionally substituted phenyl, pyridyl, -NR^6R^7, or naphthyl;

which pyridyl is further optionally substituted with one to two halo, C_1-C_3 alkyl;

R^3 is C_1-C_4 alkyl, optionally substituted phenyl, -$C(O)$-R^4, or -$S(O)_2$-R^4,
which C_1-C_4 alkyl is further optionally substituted with R^4;

R^4 is optionally substituted phenyl;

or R^2 and R^3, together with the nitrogen to which they are attached, form a 4-11 membered heterocyclic ring,

which heterocyclic ring is further optionally substituted with one to four substituents independently selected from the group consisting of optionally substituted phenyl, C_3-C_6 cycloalkyl, pyridyl, halo, hydroxy, oxo, and C_1-C_4 alkyl;

wherein the C_1-C_4 alkyl is further optionally substituted with one to two substituents selected from the group consisting of C_1-C_3 alkoxy, optionally substituted phenyl, oxo, phenoxy, pyridyl, and pyrrolidinyl;

R^6 and R^7 are each independently hydrogen, C_1-C_4 alkyl, $-S(O)_2$-CH_3, or C_1-C_4 alkoxycarbonyl, or R^6 and R^7, together with the nitrogen to which they are attached, form a 4-7 membered saturated heterocyclic ring;

R^5 is hydrogen, halo, trifluoromethyl, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_3-C_6 cycloalkyl, furyl, pyrazolyl, imidazolyl, -$NR^{13}R^{14}$, pyridyloxy, benzyloxy, phenyl, phenoxy, pyrrolyl, thienyl, phenylthio, or anilino,

which phenyl, phenoxy, pyrrolyl, thienyl, phenylthio, or anilino group may be optionally substituted on the ring with one to two substituents independently selected

from the group consisting of halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, trifluoromethyl, and –$S(O)_q$(C_1-C_4 alkyl),

or R^5 is a radical selected from the group consisting of:



(IC) , and



(ID) ;

wherein

W is a bond, -CHR^{15}-, -C(O)-, -O-, -NR^{15}-, or -$S(O)_q$-;

q is 0, 1, or 2;

R^{15} is selected from the group consisting of hydrogen, hydroxy, C_1-C_4 alkyl, acetyl, carbamoyl, phenyl, benzyl, and –$S(O)_2CH_3$;

Z^1, Z^2, and Z^3 are each independently CH or nitrogen;

R^{13} and R^{14} are each independently hydrogen, C_1-C_4 alkyl, –$S(O)_2$-CH_3 or C_3-C_6 cycloalkyl;

wherein the C_1-C_4 alkyl is optionally substituted with one C_1-C_2 alkoxy or di(C_1-C_2 alkyl)amino;

or R^{13} and R^{14}, together with the nitrogen to which they are attached, form a 4-7 membered saturated heterocyclic ring;

which 4-7 membered saturated heterocyclic ring is further optionally substituted with one to two C_1-C_2 alkyl;

or a pharmaceutically acceptable salt thereof;

with the proviso that the following compounds are not claimed: [5-methyl-1-(3-pyrrolidin-1-ylpropyl)-1H-1,2,3-triazol-4-yl]piperazin-1-yl-methanone; {1-[2-(4-nitrophenyl)ethyl]-5-methyl-1H-1,2,3-triazol-4-yl}piperazin-1-yl-methanone; [1-(4-methoxybenzyl)-5-methyl-1H-1,2,3-triazol-4-yl]piperazin-1-yl-methanone; [5-methyl-1-(3-imidazol-1-ylpropyl)-1H-1,2,3-triazol-4-yl]piperazin-1-yl-methanone; (5-methyl-1-benzyl-1H-1,2,3-triazol-4-yl)piperazin-1-yl-methanone; (1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-1,4-diazepan-1-yl-methanone; [1-(3,5-bis-trifluoromethyl-benzyl)-5-morpholin-4-yl-1H-[1,2,3]triazol-4-yl]-morpholin-4-yl-methanone; 1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazole-4-carboxylic acid (2-amino-ethyl)-(2-chloro-benzyl)-amide dihydrochloride; 1-(3,5-bis-trifluoromethyl-benzyl)-5-morpholin-4-yl-1H-[1,2,3]triazole-4-carboxylic acid (2-amino-ethyl)-(2-chloro-benzyl)-amide hydrochloride; 1-(3,5-bis-trifluoromethyl-benzyl)-5-morpholin-4-yl-1H-[1,2,3]triazole-4-carboxylic acid (2-amino-ethyl)-[1-(2-chloro-phenyl)-ethyl]-amide dihydrochloride; 1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridyl-4-yl-1H-[1,2,3]triazole-4-carboxylic acid (2-amino-ethyl)-[1-(2-chloro-phenyl)-ethyl]-amide dihydrochloride; {2-[[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazole-4-carbonyl]-(2-chloro-benzyl)-amino]-ethyl}-carbamic acid tert-butyl ester; {2-[[1-(3,5-bis-trifluoromethyl-benzyl)-5-chloro-1H-[1,2,3]triazole-4-carbonyl]-(2-chloro-benzyl)-amino]-ethyl}-carbamic acid tert-butyl ester; (2-{[1-(3,5-bis-trifluoromethyl-benzyl)-5-chloro-1H-[1,2,3]triazole-4-carbonyl]-[1-(2-chloro-phenyl)-ethyl]-amino}-ethyl)-carbamic acid tert-butyl ester; (2-{[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazole-4-carbonyl]-[1-(2-chloro-phenyl)-ethyl]-amino}-ethyl)-carbamic acid tert-butyl ester; {2-[[1-(3,5-bis-trifluoromethyl-benzyl)-5-morpholin-4-yl-1H-[1,2,3]triazole-4-carbonyl]-(2-chloro-benzyl)-amino]-ethyl}-carbamic acid tert-butyl ester; and (2-{[1-(3,5-bis-trifluoromethyl-benzyl)-5-morpholin-4-yl-1H-[1,2,3]triazole-4-carbonyl]-[1-(2-chloro-phenyl)-ethyl]-amino}-ethyl)-carbamic acid tert-butyl ester.

2. (Original) The compound of **Claim 1** wherein D^4 is oxygen.

3. (Currently Amended) The compound of **Claim ~~1 or~~ 2** wherein D^2 is nitrogen.

4. (Currently Amended) The compound of **Claim[[s 1-]] 3** wherein D^1 is methylene.

5. (Currently Amended) The compound of **Claim[[s 1-]] 4** wherein R^1 is 3,5-bis-trifluoromethyl-phenyl.

6. (Currently Amended) The compound of **Claim[[s 1-]] 5** wherein R^5 is phenyl.

7. (Currently Amended) The compound of **Claim[[s 1-]] 6** wherein R^2 is C_1-C_4 alkyl, which is optionally substituted with optionally substituted phenyl.

8. (Original) The compound of **Claim 7** wherein R^2 is 2-chloro-benzyl.

9. (Currently Amended) The compound of **Claim[[s 1-]] 8** wherein R^3 is C_1-C_4 alkyl, which C_1-C_4 alkyl is optionally substituted with R^4.

10. (Original) The compound of **Claim 9** wherein R^3 is methyl.

11. (Currently Amended) The compound of **Claim[[s 1-]] 6** wherein R^2 and R^3, together with the nitrogen to which they are attached, form a 4-11 membered heterocyclic ring, which heterocyclic ring is further optionally substituted with one to four substituents independently selected from the group consisting of optionally substituted phenyl, C_3-C_6 cycloalkyl, pyridyl, halo, hydroxy, oxo, and C_1-C_4 alkyl,

wherein the C_1-C_4 alkyl is further optionally substituted with one to two substituents selected from the group consisting of C_1-C_3 alkoxy, optionally substituted phenyl, oxo, phenoxy, pyridyl, and pyrrolidinyl.

12. (Original) The compound of **Claim 11** wherein R^2 and R^3, together with the nitrogen to which they are attached, form pyrrolidin-1-yl, which pyrrolidin-1-yl is further optionally substituted with one to four substituents independently selected from the group consisting of optionally substituted phenyl, C_3-C_6 cycloalkyl, pyridyl, halo, hydroxy, oxo, and C_1-C_4 alkyl,

wherein the C_1-C_4 alkyl is further optionally substituted with one to two substituents selected from the group consisting of C_1-C_3 alkoxy, optionally substituted phenyl, oxo, phenoxy, pyridyl, and pyrrolidinyl.

13. (Original) The compound of **Claim 12** wherein R^2 and R^3, together with the nitrogen to which they are attached, form 2-(2-chloro-phenyl)-pyrrolidin-1-yl.

14. (Original) The compound of **Claim 1** wherein the compound is 1-(3,5-Bis-trifluoromethyl-benzyl)-5-phenyl-1H-[1,2,3]triazole-4-carboxylic acid (2-chloro-benzyl)-methyl-amide.

15. (Original) The compound of **Claim 1** wherein the compound is [1-(3,5-Bis-trifluoromethyl-benzyl)-5-phenyl-1H-[1,2,3]triazol-4-yl]-[2-(2-chloro-phenyl)-pyrrolidin-1-yl]-methanone.

16. (Original) A pharmaceutical composition comprising a compound of **Claim 1**, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, excipient, or diluent.

17. (Original) A method for treating a condition associated with an excess of tachykinins, comprising: administering to a patient in need thereof an effective amount of a compound of Formula (I):



(I)

wherein:

D^1 is a C_1-C_3 alkane-diyl;

D^2 is CH or nitrogen;

D^4 is oxygen or sulfur;

R^1 is phenyl,

which phenyl is optionally substituted with one to three substitutents independently selected from the group consisting of halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy;

R^2 is selected from the group consisting of hydroxy, C_1-C_4 alkyl, optionally substituted phenyl, naphthyl, C_3-C_{10} cycloalkyl, pyridyl, optionally substituted pyrrolidinyl, optionally substituted piperidinyl,

which C_1-C_4 alkyl is optionally substituted with hydroxy, C_1-C_2 alkoxy, optionally substituted phenyl, pyridyl, -NR^6R^7, or naphthyl;

which pyridyl is further optionally substituted with one to two halo, C_1-C_3 alkyl;

R^3 is C_1-C_4 alkyl, optionally substituted phenyl, -$C(O)$-R^4, or -$S(O)_2$-R^4,

which C_1-C_4 alkyl is further optionally substituted with R^4;

R^4 is optionally substituted phenyl;

or R^2 and R^3, together with the nitrogen to which they are attached, form a 4-11 membered heterocyclic ring,

which heterocyclic ring is further optionally substituted with one to four substituents independently selected from the group consisting of optionally substituted phenyl, C_3-C_6 cycloalkyl, pyridyl, halo, hydroxy, oxo, and C_1-C_4 alkyl;

wherein the C_1-C_4 alkyl is further optionally substituted with one to two substituents selected from the group consisting of C_1-C_3 alkoxy, optionally substituted phenyl, oxo, phenoxy, pyridyl, and pyrrolidinyl;

R^6 and R^7 are each independently hydrogen, C_1-C_4 alkyl, $-S(O)_2-CH_3$, or C_1-C_4 alkoxycarbonyl, or R^6 and R^7, together with the nitrogen to which they are attached, form a 4-7 membered saturated heterocyclic ring;

R^5 is hydrogen, halo, trifluoromethyl, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_3-C_6 cycloalkyl, furyl, pyrazolyl, imidazolyl, $-NR^{13}R^{14}$, pyridyloxy, benzyloxy, phenyl, phenoxy, pyrrolyl, thienyl, phenylthio, or anilino,

which phenyl, phenoxy, pyrrolyl, thienyl, phenylthio, or anilino group may be optionally substituted on the ring with one to two substituents independently selected from the group consisting of halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, trifluoromethyl, and $-S(O)_q(C_1$-C_4 alkyl),

or R^5 is a radical selected from the group consisting of:



(IC) , and 

(ID) ;

wherein

W is a bond, $-CHR^{15}-$, -C(O)-, -O-, $-NR^{15}-$, or $-S(O)_q-$;

q is 0, 1, or 2;

R^{15} is selected from the group consisting of hydrogen, hydroxy, C_1-C_4 alkyl, acetyl, carbamoyl, phenyl, benzyl, and $-S(O)_2CH_3$;

Z^1, Z^2, and Z^3 are each independently CH or nitrogen;

R^{13} and R^{14} are each independently hydrogen, C_1-C_4 alkyl, $-S(O)_2-CH_3$ or C_3-C_6 cycloalkyl;

wherein the C_1-C_4 alkyl is optionally substituted with one C_1-C_2 alkoxy or di(C_1-C_2 alkyl)amino;

or R^{13} and R^{14}, together with the nitrogen to which they are attached, form a 4-7 membered saturated heterocyclic ring;

which 4-7 membered saturated heterocyclic ring is further optionally substituted with one to two C_1-C_2 alkyl;

or a pharmaceutically acceptable salt thereof.

18. (Original) The method of **Claim 17** wherein the condition associated with an excess of tachykinins is selected from the group consisting of depression, anxiety, irritable bowel syndrome, and emesis.

19-20. (Cancelled)

21. (Original) A compound selected from the group consisting of: [1-(3,5-Bis-trifluoromethyl-benzyl)-5-(1-oxy-pyridin-4-yl)-1H-[1,2,3]triazol-4-yl]-[2-(2-chloro-phenyl)pyrrolidin-1-yl]-methanone, [1-(3,5-Bis-trifluoromethyl-benzyl)-5-(1-oxy-pyridin-3-yl)-1H-[1,2,3]triazol-4-yl]-[2-(2-chloro-phenyl)-pyrrolidin-1-yl]-methanone, and (*R*)-[1-(3,5-Bis-trifluoromethyl-benzyl)-5-(3,6-dihydro-2H-pyridin-1-yl)-1H-[1,2,3]triazol-4-yl]-[2-(2-chloro-phenyl)-pyrrolidin-1-yl]-methanone.